Shalby Limited has successfully concluded its postal ballot process, with shareholders overwhelmingly approving the re-appointment of Mr. Shyamal Shivkumar Joshi as an Independent Director. The special resolution received strong support from the shareholder community, demonstrating confidence in the director's continued leadership.

Voting Results and Participation

The postal ballot process concluded on March 21, 2026, with results declared on March 23, 2026. The voting demonstrated significant shareholder participation and clear approval for the proposed resolution.

Director Appointment Details

The approved resolution pertains to the re-appointment of Mr. Shyamal Shivkumar Joshi (DIN: 00005766) as an Independent Director for his second consecutive term. This appointment reflects the board's commitment to maintaining experienced independent oversight.

Category-wise Voting Pattern

The voting results revealed distinct patterns across different shareholder categories, with promoters showing unanimous support while institutional and retail investors demonstrated varied responses.

Promoter and Promoter Group:

• Shares held: 8,02,78,373
• Votes polled: 8,02,78,123 (99.9997% participation)
• Support: 100.00% in favor

Public Institutions:

• Shares held: 50,33,137
• Votes polled: 3,50,749 (6.97% participation)
• Support: 0% in favor, 100.00% against

Public Non-Institutions:

• Shares held: 2,26,98,260
• Votes polled: 1,01,239 (0.45% participation)
• Support: 40.94% in favor, 59.06% against

Process and Compliance

The postal ballot was conducted entirely through remote e-voting, utilizing the services of National Securities Depository Limited (NSDL) as the service provider. The process adhered to all regulatory requirements under the Companies Act, 2013 and SEBI regulations.

The e-voting period commenced on February 20, 2026 at 9:00 AM IST and concluded on March 21, 2026 at 5:00 PM IST. Chintan Patel, Company Secretary in Practice, served as the appointed Scrutinizer for the postal ballot process, ensuring fair and transparent conduct of the voting procedure.

The cut-off date for determining eligible shareholders was February 13, 2026, and the postal ballot notice was dispatched electronically to shareholders on February 17, 2026. This appointment strengthens Shalby Limited's board composition with continued independent director expertise for the upcoming five-year term.

Shalby Limited has officially inaugurated its new oncology department at Shalby Multi-Specialty Hospital, Surat, as disclosed under Regulation 30 of SEBI (LODR) Regulations, 2015. The new department features advanced radiotherapy capabilities designed to provide comprehensive cancer treatment under one roof.

Advanced Cancer Treatment Facility

The newly inaugurated oncology department at Shalby Hospital, Surat, is equipped with state-of-the-art radiotherapy technology. This development enables the hospital to offer integrated cancer care services, allowing patients to receive complete treatment at a single location.

Expert Medical Team and Comprehensive Care

The department is supported by an experienced team of medical, radiation, and surgical oncologists, enabling patients to receive specialized diagnosis and treatment at a single location. Through advanced technology, expert medical teams, and a patient-centric approach, the hospital aims to ensure timely diagnosis and effective treatment for patients in the South Gujarat region.

Regulatory Disclosure and Strategic Expansion

The company made this announcement through a formal disclosure to NSE and BSE under Regulation 30 of SEBI (LODR) Regulations, 2015, highlighting the significance of this development. This launch aligns with Shalby Limited's strategy to enhance its healthcare infrastructure and provide advanced medical services across its network.

The addition of oncology services with radiotherapy capabilities strengthens the company's position in specialized healthcare delivery and demonstrates its commitment to providing accessible cancer care in the region.